The massive warrant overhang (1.24M existing + 536K pre-funded + 980K unregistered = ~2.76M potential shares) and the company's going concern status create persistent downward pressure. Monitor for stockholder approval of the unregistered warrants and any subsequent exercise and resale by Armistice Capital, which could accelerate selling pressure.
Price Chart
Executive Summary
bioAffinity Technologies is raising approximately $4M in net proceeds through a registered direct offering of 116,545 common shares at $6.122/share and pre-funded warrants for up to 536,836 shares, alongside a concurrent private placement of unregistered warrants for 980,072 shares. The offering is a takedown from the S-3 shelf, adding massive potential dilution from the concurrent private placement warrants and pre-funded warrants, which together could nearly double the current share count. The company has a going concern opinion from its auditor and persistent net losses, making this capital raise critical for near-term survival.
Key Facts
- Offering of 116,545 common shares at $6.122/share and pre-funded warrants for up to 536,836 shares at $6.115 each, raising ~$4M in net proceeds.
- Concurrent private placement of unregistered warrants for 980,072 shares at $6.122 exercise price, exercisable for 5 years from stockholder approval.
- Pro forma as-adjusted shares outstanding of 1,820,006, up from 452,108 actual shares as of June 30, 2026.
- Existing warrant overhang of 1,242,437 shares at a weighted average exercise price of $37.29 per share.
- Auditor's report includes a going concern explanatory paragraph; accumulated deficit of $75.55M as of June 30, 2026.
- CyPath Lung unit sales grew 100% YoY in Q3 2026, but no revenue or profitability figures are provided in this filing.
- Placement agent WallachBeth receives 7.5% fee ($299,718) plus up to $70,000 in expenses.
Financial Impact
Net proceeds of ~$4M from the offering; potential dilution of up to 1,536,908 additional shares (pre-funded + unregistered warrants) on a base of ~1.17M shares outstanding pre-offering.
Risk Factors
- Potential dilution of ~282% from the S-3 shelf registration for Armistice Capital resale, as noted in the prior S-3/A analysis.
- Going concern uncertainty with accumulated deficit of $75.55M and need for continuous capital raises.
- Unregistered warrants exercisable at $6.122 for 5 years create long-term overhang; any exercise adds further dilution.
- Stock price may decline as new shares and warrant exercises hit the market, especially given the thin float.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-046454 |
| Document: 0001493152-26-046454-index-headers.html | 0001493152-26-046454 |
| Document: 0001493152-26-046454-index.html | 0001493152-26-046454 |
| Document: 0001493152-26-046454.txt | 0001493152-26-046454 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers